.After a few years in biotech, Mike Quigley, Ph.D., is actually returning to the pharma fold, taking up the leading scientific research area at Sanofi.Quigley will begin Sept. 30 as the French Big Pharma’s chief medical policeman and worldwide director of research, Sanofi told Strong Biotech in an emailed claim.Quigley is substituting Frank Nestle, M.D., that left Sanofi this spring surrounded by an international overhaul of the business’s R&D system. Nestle, that devoted 8 years with the pharma, dove over to Deerfield Management, where he presently serves as a companion on the therapies crew and also chief executive officer of the company’s therapeutic discovery as well as progression functions.
Quigley is going to sign up with Sanofi from a San Francisco-based biotech that remains in stealth, according to his LinkedIn profile. He’s presently detailed as the provider’s co-founder, president and also chief executive officer.Due to the fact that August 2021, Quigley has actually acted as a venture companion at SV Health and wellness Investors, a health care fund manager along with existing investments in biotechs including BioAge, Cerevance, Dualitas Therapeutics and Nimbus Therapeutics, to name a few. Quigley previously kept the best area at Dualitas, a biotech that continues to be in stealth, depending on to STAT.The future Sanofi leader also earlier helmed Therini Bio, an immunotherapy biotech working to build therapies for neurodegenerative illness driven through vascular dysfunction.Before devoting the last few years in biotech, Quigley has an also longer record in Huge Pharma, very most lately working as Gilead’s senior vice head of state of research biology up until the summertime of 2021.
Prior to that, he clocked in greater than four years all over various leadership jobs at Bristol Myers Squibb and also acted as a scientific supervisor at Johnson & Johnson’s Janssen arm just before that.Sanofi mentioned Quigley’s purpose in his new function would be to “optimize our likelihood of success via optimum cooperations throughout our organization and also past, carrying best-in-class innovation along with building and sourcing brand-new industry-leading skill along with a devotion to range,” depending on to an inner memorandum secured through STAT.